Opinion|Videos|July 29, 2024
Out of Pocket Costs Associated with Biosimilar Use
The panel discusses out of pocket costs and the impact of the 340b program for various patient types.
Advertisement
Episodes in this series
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Texas Hospitals Lose $27 Million a Day in Medicaid Funding Dispute
2
Bringing CAR T-Cell Therapy Into Community Cancer Centers
3
The True Cost of Running a Community CAR T-Cell Program
4
Higher Weight-Adjusted Waist Index Tied to CKD Mortality, Study Finds
5